Superworth

Dyne Therapeutics EPS DYN

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$3.33
Latest quarter, Q2 FY26
−$1.08
Fiscal year 2025
−$3.54

Dyne Therapeutics' earnings per share was −$3.33 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.08.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.54n/a
FY2024−$3.35n/a
FY2023−$3.94n/a
FY2022−$3.24n/a
FY2021−$2.91n/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.08n/a−$3.33
Q1 FY26−$0.73n/a−$3.22
Q4 FY25−$0.76n/a−$3.54
Q3 FY25−$0.76n/a−$3.66
Q2 FY25−$0.97n/a−$3.86
Q1 FY25−$1.05n/a−$3.59
Q4 FY24−$0.88n/a−$3.35
Q3 FY24−$0.96n/a−$3.56
Q2 FY24−$0.70n/a−$3.59
Q1 FY24−$0.81n/a−$3.97
Q4 FY23−$1.09n/a−$3.94
Q3 FY23−$0.99n/a−$3.59

Against its peers

Companies in Drug Manufacturers - General nearest Dyne Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
DYNDyne Therapeutics−$3.33
OGNOrganon$0.76−60% a year
NRIXNurix Therapeutics$2.31
LQDALiquidia$1.39
ARQTArcutis Biotherapeutics$0.22
INDVIndivior Pharmaceuticals$3.57+250% a year
PBHPrestige Consumer Healthcare$3.57−16% a year
HRMYHarmony Biosciences$3.09−0% a year
LGNDLigand Pharmaceuticals$9.40
ANIPANI Pharmaceuticals$4.70
AMRXAmneal Pharmaceuticals$0.49+4800% a year
Peer median$2.70

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Dyne Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.